Anti-Infective Treatment for Burn Patients

Demegel has shown similar activity in an infected wound animal model. These results show that Demegel is equal to or superior to current treatments for eliminating an infection in wounds and burns, says Demegen, Inc. (Pittsburgh, PA, USA), the developer of Demegel. Other research has shown that the active ingredient, D2A21, is also effective against multidrug-resistant strains of Staphylococcus aureus.

Multidrug-resistant bacterial infections are an increasing problem in hospitals and other clinical settings. Drug-resistant infections acquired in the hospital nearly triple the cost and duration of hospital stay. Burn victims who are admitted to the hospital are especially vulnerable to hospital-acquired infection, due to the nature and severity of their wounds.
In fact, notes Demegen, bacterial infections and sepsis are the leading causes of death in burn patients.




Related Links:
Demegen